Literature DB >> 16172227

Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer.

Linda E Kelemen1, Thomas A Sellers, Gary L Keeney, Wilma L Lingle.   

Abstract

Folate receptor alpha (FRalpha) expression in epithelial ovarian cancer may be related to folate intake. We examined this association using multivitamin intake, a proxy for folic acid, and assessed whether the relation was modified by alcohol intake, a folate agonist. Cases (n = 148) with suspected epithelial ovarian cancer, of ages > or = 20 years, were seen at Mayo Clinic, Minnesota, between 2000 and 2004; those with tumor specimens (n = 108) were included in analyses. Outpatient controls (n = 148) without cancer and with at least one ovary intact were matched to cases by age (within 5 years) and state of residence. Multivitamin (> or = 4 pills/wk) and weekly alcohol (> or = 5 drinks) intakes were assessed. Tumor specimens were analyzed immunohistochemically for FRalpha. Multivariable rate ratios (RR) and 95% confidence intervals (CI) were estimated using unconditional logistic regression. In case-control analysis, the RRs of multivitamin intake with absent/weak/moderate and strong-expressing FRalpha tumors were 0.30 (95% CI, 0.12-0.70) and 0.47 (95% CI, 0.24-0.91), respectively. For alcohol, the associations were 0.84 (95% CI, 0.24-2.86) and 1.65 (95% CI, 0.69-3.93), respectively. In case-case analysis, the RR associated with developing strong-expressing versus other FRalpha tumors was 3.13 (95% CI, 1.14-8.65) for multivitamins and 1.58 (95% CI, 0.45-5.60) for alcohol. The data did not support evidence for an interaction between multivitamin and alcohol intake with risk of developing a strong-expressing FRalpha tumor. The association of multivitamin intake with ovarian cancer may depend on FRalpha expression level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16172227     DOI: 10.1158/1055-9965.EPI-05-0260

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  15 in total

1.  Who uses multivitamins? A cross-sectional study in the Physicians' Health Study.

Authors:  Susanne Rautiainen; Lu Wang; J Michael Gaziano; Howard D Sesso
Journal:  Eur J Nutr       Date:  2013-10-30       Impact factor: 5.614

2.  Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer.

Authors:  Chitta Ranjan Patra; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  J Mater Chem       Date:  2010-01-01

3.  Assessment of hepatocyte growth factor in ovarian cancer mortality.

Authors:  Ellen L Goode; Georgia Chenevix-Trench; Lynn C Hartmann; Brooke L Fridley; Kimberly R Kalli; Robert A Vierkant; Melissa C Larson; Kristin L White; Gary L Keeney; Trynda N Oberg; Julie M Cunningham; Jonathan Beesley; Sharon E Johnatty; Xiaoqing Chen; Katelyn E Goodman; Sebastian M Armasu; David N Rider; Hugues Sicotte; Michele M Schmidt; Elaine A Elliott; Estrid Høgdall; Susanne Krüger Kjær; Peter A Fasching; Arif B Ekici; Diether Lambrechts; Evelyn Despierre; Claus Høgdall; Lene Lundvall; Beth Y Karlan; Jenny Gross; Robert Brown; Jeremy Chien; David J Duggan; Ya-Yu Tsai; Catherine M Phelan; Linda E Kelemen; Prema P Peethambaram; Joellen M Schildkraut; Vijayalakshmi Shridhar; Rebecca Sutphen; Fergus J Couch; Thomas A Sellers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-01       Impact factor: 4.254

4.  Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Authors:  F Leung; A Dimitromanolakis; H Kobayashi; E P Diamandis; V Kulasingam
Journal:  Clin Biochem       Date:  2013-03-23       Impact factor: 3.281

5.  Folate receptor alpha as a tumor target in epithelial ovarian cancer.

Authors:  Kimberly R Kalli; Ann L Oberg; Gary L Keeney; Teresa J H Christianson; Philip S Low; Keith L Knutson; Lynn C Hartmann
Journal:  Gynecol Oncol       Date:  2008-01-28       Impact factor: 5.482

6.  Relationship between dietary and supplemental intake of folate, methionine, vitamin B6 and folate receptor alpha expression in ovarian tumors.

Authors:  Joanne Kotsopoulos; Jonathan L Hecht; Jonathan D Marotti; Linda E Kelemen; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

7.  Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome.

Authors:  Michelle K Y Siu; Daniel S H Kong; Hoi Yan Chan; Esther S Y Wong; Philip P C Ip; LiLi Jiang; Hextan Y S Ngan; Xiao-Feng Le; Annie N Y Cheung
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

8.  Functional folate receptor alpha is elevated in the blood of ovarian cancer patients.

Authors:  Eati Basal; Guiti Z Eghbali-Fatourechi; Kimberly R Kalli; Lynn C Hartmann; Karin M Goodman; Ellen L Goode; Barton A Kamen; Philip S Low; Keith L Knutson
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

Review 9.  Photocontrolled activation of small molecule cancer therapeutics.

Authors:  M Michael Dcona; Koushambi Mitra; Matthew C T Hartman
Journal:  RSC Med Chem       Date:  2020-07-31

Review 10.  Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.

Authors:  Mathieu Luyckx; Raffaella Votino; Jean-Luc Squifflet; Jean-François Baurain
Journal:  Int J Womens Health       Date:  2014-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.